All In Biotech

Free tool

FAERS Monitor: Remicade

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 103772 or its brand name (Remicade, Infliximab). Reports on generic versions are filed under their own applications.

Reports

217,587

Serious

192,742

89% of reports

Hospitalization

64,715

Death reported

14,068

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective39,857
  • off label use39,149
  • condition aggravated20,002
  • infusion related reaction19,191
  • pain18,649
  • rheumatoid arthritis18,613
  • arthralgia17,843
  • fatigue16,776
  • rash13,431
  • product use issue13,143
  • intentional product use issue13,103
  • drug intolerance12,543
  • nausea12,320
  • alopecia11,916
  • joint swelling11,686

Reports by year received

View as table
YearReports
20043,914
20053,404
20063,607
20074,090
20084,335
20095,091
20106,225
20118,099
201212,244
20139,120
20145,999
201512,316
20169,599
201710,037
201811,094
201913,337
202017,812
202113,063
202218,658
202314,184
202412,379
202512,090
20266,872

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,836,572 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infusion related reactionSignal19,19139.038.3506,167
rheumatoid arthritisSignal18,61318.818.5263,034
intentional product use issueSignal13,10316.816.5166,543
drug intoleranceSignal12,54314.314.0135,343
joint swellingSignal11,68610.310.188,647
product use issueSignal13,1437.27.165,760
condition aggravatedSignal20,0026.76.692,619
alopeciaSignal11,9166.26.149,046
off label useSignal39,1494.54.4105,382
arthralgiaSignal17,8434.34.243,943
rashSignal13,4313.03.018,210
painSignal18,6493.03.024,755
drug ineffectiveSignal39,8573.03.054,368
fatigueSignal16,7762.12.19,909
nausea12,3201.51.52,189

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.